MREO Company Profile and Key Details

Q: Who are the executives of MREO?

Dr. Suba KrishnanSenior Vice President of Clinical Devel.Dr. Alastair MacKinnon M.D., MBBSCo-Founder and Chief of Portfolio & Pipeline StrategyMs. Christine Fox CPAChief Financial OfficerDr. Fiona BorHead of Intellectual PropertyDr. John P. Richard M.B.A., MBACo-Founder & Chief Bus. OfficerDr. Denise Scots-Knight Ph.D.Co-Founder, Chief Executive Officer & Executive DirectorMs. Alexandra Hughes-WilsonChief of Patient Access & Commercial PlanningDr. John A. Lewicki Ph.D.Chief Scientific OfficerDr. Jackie ParkinSenior Vice President & Therapeutic HeadDr. Arun MistryTherapeutic Area Head of SetrusumabDr. Ann Kapoun Ph.D.Senior Vice President of Translational R&DMr. Charles SermonCo-Founder, Gen. Counsel & Company Sec.

NASDAQ : MREO

Mereo BioPharma Group

$0.24

0.0021+0.87%

At Close 4:00 PM

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Mereo BioPharma Group plc (MREO) stock surged +0.87%, trading at $0.24 on NASDAQ, up from the previous close of $0.24. The stock opened at $0.24, fluctuating between $0.24 and $0.25 in the recent session.

Stock Snapshot

0.2425

Prev. Close

39.04M

Market Cap

0.24

Day Low

-4.89

P/E Ratio

-0.05

EPS (TTM)

-0.22

Cash Flow per Share

0.24

Open

159.62M

Number of Shares

0.2489

Day High

83.03%

Free Float in %

0.37

Book Value

693.92K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 10, 2026	0.24	0.25	0.24	0.24	693.92K
Sep 09, 2026	0.26	0.26	0.24	0.24	2.95M
Sep 08, 2026	0.25	0.26	0.25	0.25	761.21K
Sep 04, 2026	0.27	0.27	0.25	0.25	1.33M
Sep 03, 2026	0.26	0.28	0.26	0.27	876.91K
Sep 02, 2026	0.27	0.28	0.26	0.27	804.9K
Sep 01, 2026	0.27	0.29	0.27	0.28	1.55M
Aug 31, 2026	0.25	0.29	0.25	0.27	1.31M
Aug 28, 2026	0.27	0.27	0.25	0.25	1.52M
Aug 27, 2026	0.29	0.29	0.27	0.27	1.42M
Aug 26, 2026	0.29	0.29	0.28	0.28	948.58K
Aug 25, 2026	0.29	0.29	0.28	0.28	1.15M
Aug 24, 2026	0.29	0.29	0.28	0.29	797.78K
Aug 21, 2026	0.30	0.31	0.29	0.29	693.77K
Aug 20, 2026	0.31	0.31	0.29	0.29	748.61K
Aug 19, 2026	0.29	0.31	0.28	0.31	1.21M
Aug 18, 2026	0.31	0.32	0.30	0.31	979.46K
Aug 17, 2026	0.32	0.32	0.30	0.31	1.44M
Aug 14, 2026	0.30	0.33	0.30	0.32	1.83M
Aug 13, 2026	0.30	0.31	0.29	0.31	2.29M

Contact Details

London, GL W1G 0QF

United Kingdom

https://www.mereobiopharma.com 443 330 237300

About Company

Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.

Stock Peers

ARGX

-18.27-1.82%

argenx SE$984.04 REGN

-14.39-1.78%

Regeneron Pharmaceuticals, Inc.$793.26 MDGL

-13.54-2.48%

Madrigal Pharmaceuticals, Inc.$533.12 VRTX

-6.56-1.26%

Vertex Pharmaceuticals Incorporated$514.56 UTHR

-2.96-0.58%

United Therapeutics Corporation$503.86 KRYS

-2.54-0.73%

Krystal Biotech, Inc.$345.55 ONC

-9.2-2.62%

BeOne Medicines AG$341.80 PRAX

-6.73-1.95%

Praxis Precision Medicines, Inc.$338.57 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

1.2+0.42%

Ligand Pharmaceuticals Incorporated$289.25

Company Overview

The stock is currently mid-range between its 52-week high and low $0.20 and $2.37. With a market capitalization of about $39.04 million, Mereo BioPharma Group plc is classified as a micro-cap and shows lower-than-market volatility (beta ~0.30). Key stats such as the average daily volume over the past year has been around 4.05 million shares, volume is running light vs its 52-week average. Headquartered in London, GL, Mereo BioPharma Group plc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Denise Vera Scots-Knight, the company employs approximately 39 people and listed since April 24, 2019. Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions.

Technical Performance

MREO has shown mixed momentum, losing -0.39% over the past week and -72.43% over the past quarter, though year-to-date performance is up 35.61%. Short-term trend indicators are bullishly aligned (SMA20 -5.51%, SMA50 -49.28%, SMA200 -77.51%). The stock’s 14-day RSI is 34.68 (weak momentum), while the ATR of 0.06 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -87.34% below its high and over 93.0% above its low. Average 10-day trading volume of 1.28 million shares is below the 3-month average of 3.96 million, indicating normal recent market interest.

Valuation Metrics

Mereo BioPharma Group plc trades at a P/E ratio of -1.35, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.37 suggesting the stock is closer to book value. The P/FCF stands at -1.54, also below market averages.

Dividend & Fair Value

Mereo BioPharma Group plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.26. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Mereo BioPharma Group plc generated EPS of -$0.26 over the past year. Five-year average earnings growth is 34.82%. Wall Street analysts project EPS growth of 12.64% annually over the next five years. The latest quarter delivered EPS of -$0.01. The next quarter is forecast at -$0.01. Next year's EPS is expected at $91.77. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $1.00. The high target offers 2816.67% upside. The low target suggests 316.67% downside. The mean target is $4.14. This offers 1625.0% upside. Mereo BioPharma Group plc earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 11, 2026, missed forecasts by 0.0%. The prior quarter beat by -150.0%. Over the last six quarters, Apple has recorded several small beats. These include 100.0% in May 13, 2025.

Shareholding & Insider Activity

Mereo BioPharma Group plc has 159.13 million shares outstanding. The public float is 537.96 million shares, elevated short interest at 12.45% of float. This equals 14.09 million shares. The short ratio is 1.56 days. Institutional investors hold 48.25% of the float. Insiders own 0.75%. Scots-Knight Denise holds 808.92 thousand shares, Sermon Charles has 219.06 thousand shares and Fox Christine Ann has 89.28 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Mereo BioPharma Group generated $10.00M in revenue, or $0.00 per share. Gross margin was 74.26%, operating margin -284.16%, and net profit margin -294.66%. Returns are negative, with ROA at -44.31% and ROE at -58.31%.
On valuation metrics, Mereo BioPharma Group trades at a P/E of -1.35, P/S of 0.00 and P/B of 1.37. The current ratio is 5.88 and quick ratio is 5.88. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -456.34 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.04, supported by a cash flow-to-debt ratio of -24.61.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Mereo BioPharma Group posted revenue of $10.00M, down slightly from $1.51M in the prior quarter. Gross profit was $7.43M (margin 74.26%). Operating income was - $28.42M (margin -284.2%). Net income was- $29.47M (EPS $0.00).
The company ended the quarter with $57.42M in cash and short-term investments, a total debt of $5.95M, and net debt of - $51.47M. Total assets were $66.50M, with equity of $50.54M. Financials further reflected weakness, with operating cash flow of - $21.13M, free cash flow of - $21.55M, and capital expenditures of - $419.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Mereo BioPharma Group plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.06%, with price expected at $0.22 by September 23, 2026, within a range of $0.20 to $0.23 3-Month Outlook: Projected rise of 75.8%, reaching $0.43 by December 08, 2026, with a range of $0.36 to $0.50. 1-Year Outlook: Projected loss of -95.91%, with price at $0.01 by September 09, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Mereo BioPharma Group plc (NASDAQ:MREO) shares are up 35.61% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Mereo BioPharma Group plc trading at a premium to the broader market with a P/E of -1.35. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.09, suggesting 2389.78% upside. Our AI forecast model points to short-term weakness (-10.06% over two weeks), a medium-term rise (75.8% over three months), and a longer-term loss (-95.91% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Mereo BioPharma Group plc (MREO) stock price?

Mereo BioPharma Group plc (NASDAQ: MREO) stock price is $0.24 in the last trading session. During the trading session, MREO stock reached the peak price of $0.25 while $0.24 was the lowest point it dropped to. The percentage change in MREO stock occurred in the recent session was 0.87% while the dollar amount for the price change in MREO stock was $0.00.

MREO's industry and sector of operation?

The NASDAQ listed MREO is part of Biotechnology industry that operates in the broader Healthcare sector. Mereo BioPharma Group plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MREO?

Dr. Suba Krishnan
Senior Vice President of Clinical Devel.
Dr. Alastair MacKinnon M.D., MBBS
Co-Founder and Chief of Portfolio & Pipeline Strategy
Ms. Christine Fox CPA
Chief Financial Officer
Dr. Fiona Bor
Head of Intellectual Property
Dr. John P. Richard M.B.A., MBA
Co-Founder & Chief Bus. Officer
Dr. Denise Scots-Knight Ph.D.
Co-Founder, Chief Executive Officer & Executive Director
Ms. Alexandra Hughes-Wilson
Chief of Patient Access & Commercial Planning
Dr. John A. Lewicki Ph.D.
Chief Scientific Officer
Dr. Jackie Parkin
Senior Vice President & Therapeutic Head
Dr. Arun Mistry
Therapeutic Area Head of Setrusumab
Dr. Ann Kapoun Ph.D.
Senior Vice President of Translational R&D
Mr. Charles Sermon
Co-Founder, Gen. Counsel & Company Sec.

How MREO did perform over past 52-week?

MREO's closing price is 22.3% higher than its 52-week low of $0.20 where as its distance from 52-week high of $2.37 is -89.68%.

How many employees does MREO have?

Number of MREO employees currently stands at 39.

Link for MREO official website?

Official Website of MREO is: https://www.mereobiopharma.com

How do I contact MREO?

MREO could be contacted at phone 443 330 237300 and can also be accessed through its website. MREO operates from One Cavendish Place, London, GL W1G 0QF, United Kingdom.

How many shares of MREO are traded daily?

MREO stock volume for the day was 693.92K shares. The average number of MREO shares traded daily for last 3 months was 4.05M.

What is the market cap of MREO currently?

The market value of MREO currently stands at $39.04M with its latest stock price at $0.24 and 159.62M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	39
Beta	0.3
Sales or Revenue	$10.00M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

MREO Company Profile and Key Details

Mereo BioPharma Group

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook